The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1611
ISSUE 1611
November 16, 2020
Orphengesic Forte - An Old Analgesic Combination Returns
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
November 16, 2020 (Issue: 1611)
A fixed-dose combination of orphenadrine citrate, aspirin,
and caffeine (Orphengesic Forte – Galt; previously
available as Norgesic Forte) has been approved as
a prescription drug by the FDA for treatment of mild
to moderate pain caused by acute musculoskeletal
disorders. Single-ingredient generic orphenadrine
citrate is available by prescription in oral and injectable
formulations and has been used for years as an adjunct
for treatment of acute musculoskeletal pain. Orphengesic
Forte is being marketed as a non-opioid alternative for
pain relief.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Orphengesic Forte - An Old Analgesic Combination Returns
Article code: 1611d
Electronic, downloadable article - $45
Article code: 1611d
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
